Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abeona Therapeutics (ABEO) EPS (Weighted Average and Diluted) (2022 - 2025)

Abeona Therapeutics (ABEO) has 8 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.12 in Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) rose 80.95% year-over-year to -$0.12; the TTM value through Sep 2025 reached $1.21, up 145.83%, while the annual FY2024 figure was -$1.55, 38.74% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.12 in Q3 2025 per ABEO's latest filing, down from $1.71 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $1.71 in Q2 2025 and bottomed at -$1.16 in Q1 2024.
  • Average EPS (Weighted Average and Diluted) over 4 years is -$0.28, with a median of -$0.51 recorded in 2023.
  • Peak YoY movement for EPS (Weighted Average and Diluted): tumbled 167.65% in 2023, then skyrocketed 757.69% in 2025.
  • A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.9 in 2022, then soared by 34.67% to -$0.59 in 2023, then skyrocketed by 76.27% to -$0.14 in 2024, then grew by 14.29% to -$0.12 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$0.12 in Q3 2025, $1.71 in Q2 2025, and -$0.24 in Q1 2025.